Objective response (CR or PR) was reported for four patients (one CR and three PR; 8.3%), which is similar to the objective response rates reported in previous studies of the MAGE-A3 immunotherapeutic in patients with metastatic melanoma,15 21 and much lower than what is observed with new checkpoint blockers immunotherapy. Here, MAGEA3 is linked to metastatic melanoma.